NASDAQ:ATYR aTyr Pharma (ATYR) Stock Price, News & Analysis $3.82 +0.13 (+3.52%) Closing price 04:00 PM EasternExtended Trading$3.82 0.00 (0.00%) As of 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About aTyr Pharma Stock (NASDAQ:ATYR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get aTyr Pharma alerts:Sign Up Key Stats Today's Range$3.80▼$4.1550-Day Range$3.69▼$17.1952-Week Range$3.69▼$44.40Volume90,514 shsAverage Volume67,096 shsMarket Capitalization$9.74 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingHold Company Overview aTyr Pharma is a clinical-stage biotechnology company focused on developing medicines based on the extracellular biology of tRNA synthetases, a family of proteins involved in cellular processes. The company is headquartered in San Diego, California. Its lead drug candidate, efzofitimod, is an immunomodulator being studied for pulmonary sarcoidosis and other interstitial lung diseases. The candidate is designed to act through neuropilin-2, a receptor involved in immune regulation. aTyr’s research programs draw on its work in tRNA synthetase biology, with the broader goal of developing treatments for inflammatory and fibrotic conditions. Its activities center on drug research and clinical development.AI Generated. May Contain Errors. Read More aTyr Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreATYR MarketRank™: 3.23146498561 of 5 starsaTyr Pharma scored higher than 65% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingaTyr Pharma has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 strong buy rating, 1 buy rating, 3 hold ratings, and 1 sell rating.Upside PotentialaTyr Pharma has a consensus price target of $5.00, representing about 29.5% upside from its current price of $3.86.Amount of Analyst CoverageaTyr Pharma has only been the subject of 4 research reports in the past 90 days.Read more about aTyr Pharma's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for aTyr Pharma are expected to grow in the coming year, from ($22.96) to ($17.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of aTyr Pharma is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of aTyr Pharma is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioaTyr Pharma has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted12.60% of the float of aTyr Pharma has been sold short.Short Interest Ratio / Days to CoveraTyr Pharma has a short interest ratio ("days to cover") of 3.37, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in aTyr Pharma has recently decreased by 97.14%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldaTyr Pharma does not currently pay a dividend.Dividend GrowthaTyr Pharma does not have a long track record of dividend growth. News and Social Media1.2 / 5News Sentiment-0.02 News SentimentaTyr Pharma has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for aTyr Pharma this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for ATYR on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added aTyr Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, aTyr Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders5.03% of the stock of aTyr Pharma is held by insiders.Percentage Held by Institutions61.72% of the stock of aTyr Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about aTyr Pharma's insider trading history. Receive ATYR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATYR Stock News HeadlinesATyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the Connective Tissue Oncology Society 2026 Annual MeetingNovember 19 at 9:02 AM | marketscreener.comMaTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the Connective Tissue Oncology Society (CTOS) 2026 Annual MeetingNovember 19 at 7:00 AM | globenewswire.comA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th.November 20 at 1:00 AM | Behind the Markets (Ad)aTyr Pharma (NASDAQ:ATYR) Stock Rating Lowered by Wall Street ZenNovember 14, 2026 | americanbankingnews.comaTyr Pharma (ATYR) Stock Fair Value Moves Lower As Phase III Funding Risks LoomNovember 13, 2026 | finance.yahoo.comFY2026 EPS Estimate for aTyr Pharma Reduced by AnalystNovember 12, 2026 | americanbankingnews.comaTyr Pharma to Participate in Upcoming Investor ConferencesNovember 11, 2026 | globenewswire.comaTyr Pharma, Inc. (ATYR) - What Are Brokerages Saying About This Stock?November 11, 2026 | americanbankingnews.comSee More Headlines ATYR Stock Analysis - Frequently Asked Questions How have ATYR shares performed this year? aTyr Pharma's stock was trading at $31.3240 on January 1st, 2026. Since then, ATYR stock has decreased by 87.7% and is now trading at $3.86. How were aTyr Pharma's earnings last quarter? aTyr Pharma, Inc. (NASDAQ:ATYR) announced its earnings results on Friday, November, 6th. The company reported ($7.43) EPS for the quarter, missing the consensus estimate of ($4.00) by $3.43. When did aTyr Pharma's stock split? Shares of aTyr Pharma reverse split on the morning of Thursday, October 29th 2026.A 1-40 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 28th 2026. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did aTyr Pharma IPO? aTyr Pharma (ATYR) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,360,000 shares at a price of $13.00-$15.00 per share. How do I buy shares of aTyr Pharma? Shares of ATYR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of aTyr Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that aTyr Pharma investors own include NVIDIA (NVDA), Archer Aviation (ACHR), Amprius Technologies (AMPX), BigBear.ai (BBAI), Applied Digital (APLD), Grab (GRAB) and Intel (INTC). Company Calendar Last Earnings11/06/2026Today11/20/202638th Annual Healthcare Conference12/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ATYR's financial health is in the Red zone, according to TradeSmith. ATYR has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ATYR Previous SymbolNASDAQ:ATYR CIK1339970 Webatyrpharma.com Phone(858) 731-8389Fax858-731-8394Employees58Year Founded2005Price Target and Rating Average Price Target for aTyr Pharma$5.00 High Price Target$6.00 Low Price Target$4.00 Potential Upside/Downside+30.9%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($21.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$74.12 million Net MarginsN/A Pretax Margin-32,006.32% Return on Equity-102.83% Return on Assets-70.56% Debt Debt-to-Equity RatioN/A Current Ratio3.05 Quick Ratio3.05 Sales & Book Value Annual Sales$190 thousand Price / Sales51.27 Cash FlowN/A Price / Cash FlowN/A Book Value$13.26 per share Price / Book0.29Miscellaneous Outstanding Shares2,550,000Free Float2,421,000Market Cap$9.74 million OptionableOptionable Beta1.04 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:ATYR) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredAre Tesla and SpaceX Going Bankrupt?Tesla and SpaceX shares crashed right after Democrats took the House and the Senate in the midterm election. E...Brownstone Research | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored6 Men Secretly Changed America’s Money. Now It’s Happening AgainIn 1910, six powerful men secretly met to lay the groundwork for the Federal Reserve, reshaping America's fina...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding aTyr Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share aTyr Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.